Webinar: Long COVID - Managing long term health consequences of COVID-19

Location: Virtual Session,
Date: 23 March 2022 6:30pm to 23 March 2022 08:00pm

Health services planning for COVID-19 has understandably focused on mortality, hospital admissions and intensive care capacity, alongside vaccination and public health control measures. However, concerns about the long-term consequences of the pandemic are increasingly focused on the long-term clinical sequelae being seen in survivors of COVID-19. 

Collectively referred to as Long COVID, a significant minority of patients report suffering from extended COVID-related medical conditions for weeks or even months post-infection. Although Long COVID is not yet fully understood, it has already placed a significant burden on countries which have suffered more acutely from the pandemic than Australia. As Australia has reopened and caseloads have risen, health policy makers in Australia should be preparing to address Long COVID. 

In this webinar, we will explore the hospital experience of Long COVID in Israel; examine the likely burden and health system impacts of Long COVID and post-COVID illness in Australia and discuss the development of Australian evidence-based clinical guidelines for Long COVID. 

Speakers include:  

  • Dr Itzchak Levy - Director at Infectious Disease Institute, Sheba Medical Center, Israel 
  • Prof Martin Hensher - Menzies Centre for Medical Research, University of Tasmania 
  • Prof Mark Morgan - National COVID-19 Clinical Evidence Taskforce 

Speakers

Dr Itzchak Levy - Director of HIV/AIDS and Infectious Disease Outpatient Clinic, Sheba Medical Centre (Israel)
Itzchak Levy graduated medical school at the Hadassah Medical School and the Hebrew University in Jerusalem in 1987. He did his fellowship in infectious diseases at the Sheba Medical Center in 1991. In 1992 he established the Israeli AIDS Hospice and the HIV and STDs unit at the Sheba Medical Center. In 2007 he was among the founders of the Israeli Medical HIV/AIDS and counsels for the Israeli AIDS task force. In addition to his clinical work, Itzchak is also involved in academic work and has conducted many studies which have been published in over sixty articles. He is also involved in international clinical studies. Since 2020, his research has focussed on the immunogenicity of the mRNA COVID-19 vaccine among immunocompromised patients and has established the Long COVID Clinic at the Sheba Medical Center. 

Prof Martin Hensher - Henry Baldwin Professorial Research Fellow, Menzies Institute for Medical Research, University of Tasmania  
Martin has 30 years' experience as a healthcare policy maker and health economist. Originally from the UK, he has worked in the National Health Service, as a consultant for the World Bank in Central Asia, the European Commission and the South African National Department of Health, and as Senior Economic Advisor to the UK Department of Health. Previously, he was a senior executive in the Tasmanian Department of Health. His research focuses on the economics and organisation of sustainable health systems for the future, using insights and principles from ecological economics. 

Prof Mark Morgan - Co-chair of the National COVID-19 Clinical Evidence Taskforce Mild and Chronic Care Panel.
Prof Mark Morgan trained in general practice in the UK. He has worked both in rural and urban Australia as a GP, educator and researcher. His research interests include patient safety, primary care data, shared decision making and the management of patients with multiple long-term medical conditions. Mark holds a senior leadership role with the RACGP as the chair of the Expert Committee for Quality Care responsible for guidelines and representing the College on national committees. Mark is the Associate Dean for External Engagement and teaches within the Medical Program at the Faculty of Health, Science and Medicine, Bond University.